Summit Therapeu ADR (SMMT)

$21.27 +0.35 (1.67%)
Market Cap 15.54B
Revenue (ttm) 0.00
Net Income (ttm) -221.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,067,400
Avg Vol 5,083,264
Day's Range N/A - N/A
Shares Out 742.67M
Stochastic %K 79%
Beta -1.06
Analysts Strong Sell
Price Target $34.55

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology
Sector: Healthcare
Phone: 305-203-2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
TruthBroker2
TruthBroker2 Jun. 26 at 2:27 PM
$SMMT
0 · Reply
yepper69
yepper69 Jun. 26 at 1:47 PM
$SMMT good time to get in? Asking for my wife’s boyfriend
1 · Reply
FrankRoss235
FrankRoss235 Jun. 26 at 12:35 PM
$SMMT reached a point of resistance
0 · Reply
TruthBroker2
TruthBroker2 Jun. 26 at 12:15 PM
$SMMT
0 · Reply
yus37
yus37 Jun. 26 at 11:08 AM
$IOVA If you're a big pharma exec looking to expand into cell therapy, IOVA has to be on your radar. Their product isn’t easily replaced. Execution issues can be fixed with the right backing. I'm positioning now before that narrative catches on.... Not financial advice..just my 2 cents...Lol.. $IMRX $IBRX $SMMT $XBI
2 · Reply
SmokeWagon
SmokeWagon Jun. 25 at 10:18 PM
$SMMT
0 · Reply
EB2224
EB2224 Jun. 25 at 8:24 PM
$SMMT
0 · Reply
SenorDG
SenorDG Jun. 25 at 6:17 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Jun. 25 at 6:16 PM
$SMMT
0 · Reply
jewell69
jewell69 Jun. 25 at 6:11 PM
$SMMT TRYIN 2 BUY 21.04 RECENT TRADES 06/16/2025 Sell Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $20.43 $0.04 $5,107.46 06/13/2025 Buy Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.67 -$4,917.50 06/05/2025 Sell Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.7204 $0.04 $4,930.06 06/05/2025 Buy Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.58 -$4,895.00 06/05/2025 Sell Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.86 $0.04 $4,964.96 06/05/2025 Buy Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.65 -$4,912.50
0 · Reply
Latest News on SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2025, 4:44 PM EDT - 19 days ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 21 days ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 2:52 PM EDT - 23 days ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Is SMMT Stock A Buy After Its Recent Plunge?

Jun 2, 2025, 9:10 AM EDT - 24 days ago

Is SMMT Stock A Buy After Its Recent Plunge?

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 2:50 PM EDT - 26 days ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:27 AM EDT - 27 days ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 9:01 AM EDT - 27 days ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 30, 2025, 6:00 AM EDT - 27 days ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

May 2, 2025, 1:06 AM EDT - 7 weeks ago

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 7 weeks ago

Final Trade: NVS, XLU and SMMT

NVS XLU

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 1, 2025, 4:09 PM EDT - 7 weeks ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Apr 28, 2025, 1:00 PM EDT - 2 months ago

Why Is Summit Therapeutics Stock Trading Higher On Monday?

What's Going On With Summit Therapeutics Stock On Friday?

Apr 25, 2025, 3:14 PM EDT - 2 months ago

What's Going On With Summit Therapeutics Stock On Friday?

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 25, 2025, 2:50 PM EDT - 2 months ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 24, 2025, 4:15 PM EDT - 2 months ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Apr 23, 2025, 3:47 PM EDT - 2 months ago

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 23, 2025, 6:15 AM EDT - 2 months ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Apr 14, 2025, 9:08 AM EDT - 2 months ago

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Mar 24, 2025, 2:17 PM EDT - 3 months ago

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Mar 17, 2025, 4:24 PM EDT - 3 months ago

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Feb 24, 2025, 8:13 PM EST - 4 months ago

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

PFE

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Feb 24, 2025, 3:33 PM EST - 4 months ago

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 12:15 PM EST - 4 months ago

Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

Pfizer: What The Summit Therapeutics Deal Brings

Feb 24, 2025, 10:53 AM EST - 4 months ago

Pfizer: What The Summit Therapeutics Deal Brings

PFE

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Feb 24, 2025, 6:05 AM EST - 4 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

Feb 24, 2025, 6:00 AM EST - 4 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

PFE

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Feb 18, 2025, 9:00 AM EST - 4 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Jan 18, 2025, 9:33 AM EST - 5 months ago

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 5 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 6 months ago

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Best-Performing Stocks Of 2024

Jan 2, 2025, 11:46 PM EST - 6 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD JANX LUNR

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Dec 2, 2024, 2:10 PM EST - 7 months ago

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Summit Therapeutics to Present at Upcoming Investor Conferences

Nov 26, 2024, 4:15 PM EST - 7 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

Nov 4, 2024, 2:14 PM EST - 8 months ago

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 1:27 PM EDT - 8 months ago

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Oct 30, 2024, 7:00 AM EDT - 8 months ago

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

Oct 23, 2024, 4:15 PM EDT - 8 months ago

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track

Oct 4, 2024, 10:35 AM EDT - 9 months ago

Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Oct 3, 2024, 4:15 PM EDT - 9 months ago

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19, 2024, 2:33 PM EDT - 9 months ago

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

MRK

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

Sep 16, 2024, 6:30 AM EDT - 10 months ago

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

Trade It or Fade It: The week's big biotech moves

Sep 13, 2024, 6:52 PM EDT - 10 months ago

Trade It or Fade It: The week's big biotech moves

BNTX MRK

Summit Therapeutics Raises $235 Million

Sep 12, 2024, 6:30 AM EDT - 10 months ago

Summit Therapeutics Raises $235 Million

Summit Therapeutics Co-CEOs on what's next for lung cancer drug

Sep 11, 2024, 6:28 PM EDT - 10 months ago

Summit Therapeutics Co-CEOs on what's next for lung cancer drug

Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation

Sep 9, 2024, 12:45 PM EDT - 10 months ago

Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation

BA Reaches Union Deal, COST Price Target Hike, MRK Down as SMMT Rallies

Sep 9, 2024, 10:17 AM EDT - 10 months ago

BA Reaches Union Deal, COST Price Target Hike, MRK Down as SMMT Rallies

BA COST MRK

Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today

Sep 9, 2024, 9:57 AM EDT - 10 months ago

Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today

TruthBroker2
TruthBroker2 Jun. 26 at 2:27 PM
$SMMT
0 · Reply
yepper69
yepper69 Jun. 26 at 1:47 PM
$SMMT good time to get in? Asking for my wife’s boyfriend
1 · Reply
FrankRoss235
FrankRoss235 Jun. 26 at 12:35 PM
$SMMT reached a point of resistance
0 · Reply
TruthBroker2
TruthBroker2 Jun. 26 at 12:15 PM
$SMMT
0 · Reply
yus37
yus37 Jun. 26 at 11:08 AM
$IOVA If you're a big pharma exec looking to expand into cell therapy, IOVA has to be on your radar. Their product isn’t easily replaced. Execution issues can be fixed with the right backing. I'm positioning now before that narrative catches on.... Not financial advice..just my 2 cents...Lol.. $IMRX $IBRX $SMMT $XBI
2 · Reply
SmokeWagon
SmokeWagon Jun. 25 at 10:18 PM
$SMMT
0 · Reply
EB2224
EB2224 Jun. 25 at 8:24 PM
$SMMT
0 · Reply
SenorDG
SenorDG Jun. 25 at 6:17 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 Jun. 25 at 6:16 PM
$SMMT
0 · Reply
jewell69
jewell69 Jun. 25 at 6:11 PM
$SMMT TRYIN 2 BUY 21.04 RECENT TRADES 06/16/2025 Sell Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $20.43 $0.04 $5,107.46 06/13/2025 Buy Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.67 -$4,917.50 06/05/2025 Sell Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.7204 $0.04 $4,930.06 06/05/2025 Buy Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.58 -$4,895.00 06/05/2025 Sell Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.86 $0.04 $4,964.96 06/05/2025 Buy Trade Details SMMT SUMMIT THERAPEUTICS INC 250 $19.65 -$4,912.50
0 · Reply
Newyork_
Newyork_ Jun. 25 at 2:55 PM
$SMMT https://youtu.be/qNTnVRBuveY?si=ZMyRcnuL5QyGpJmn Maky said looking to file BLA by end of 2025 / and looking to hit the market end of 2026 ish. ✨💫🔥🔥🔥
0 · Reply
TruthBroker2
TruthBroker2 Jun. 25 at 7:54 AM
$SMMT
0 · Reply
___dog___
___dog___ Jun. 25 at 3:05 AM
$SMMT good luck
0 · Reply
___dog___
___dog___ Jun. 25 at 3:02 AM
$SMMT that little spike protein thing on the daily candle today is a warning for y'all. You may want to buy some trojans
0 · Reply
Teluride
Teluride Jun. 24 at 10:52 PM
$SMMT The Eagle broke through the old sky-mark — the 200-day moving average — carried by the voice of the tribe and rising volume winds. But with the feathers hot from flight, the elders whisper: “Do not chase the sun with a weary wing.” The spirit line of $22 stands ahead. If the drums beat steady and the fire doesn’t burn too bright, the Eagle may climb again. #SMMT #200DayBreak #VolumeRising #RSIWatching #TribalMomentum
0 · Reply
CAN_2409
CAN_2409 Jun. 24 at 6:20 PM
$SMMT was a great win! Now you need more CADL!
1 · Reply
TruthBroker2
TruthBroker2 Jun. 24 at 4:48 PM
$SMMT
0 · Reply
Topcaller
Topcaller Jun. 24 at 4:39 PM
I shorted heavy $SMMT at 21.75 look at May 15 low and thats all you need to know
0 · Reply
TruthBroker2
TruthBroker2 Jun. 24 at 3:22 PM
$SMMT
0 · Reply
BooEmmy
BooEmmy Jun. 24 at 2:00 PM
$SMMT Oh I forgot to mention that they are leasing the space from Ascendis Pharma (ASND), a large pharma company from Europe that , according to Yahoo finance,- ' It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. ' That seems interesting to me. $25 by end of week.
0 · Reply
BooEmmy
BooEmmy Jun. 24 at 1:46 PM
$SMMT Interesting that smmt is going to lease 36k sq feet of space in Palo Alto starting Jan 1 next year.
0 · Reply
BooEmmy
BooEmmy Jun. 24 at 1:37 PM
$SMMT
0 · Reply